| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development expenses | 521,069 | 732,315 | - | - |
| General and administrative expenses | 1,243,009 | 1,150,397 | - | - |
| Total operating expenses | 1,764,078 | 1,882,712 | - | - |
| Loss from operations | -1,764,078 | -1,882,712 | -2,267,293 | -2,211,474 |
| Interest income | 47,860 | 23,747 | - | - |
| Loss on equity method investment | -76,920 | -98,730 | - | - |
| Inducement expense | - | 0 | - | - |
| Other income (expenses) | -513 | -861 | - | - |
| Total other income (expense) | -29,573 | -75,844 | - | - |
| Net loss | -1,793,651 | -1,958,556 | -2,228,801 | -2,191,803 |
| Loss per share, basic (in dollars per share) | -0.08 | -0.18 | -0.34 | -0.38 |
| Loss per share, diluted (in dollars per share) | -0.08 | -0.18 | -0.34 | -0.38 |
| Weighted average shares, basic (in shares) | 22,171,309 | - | - | - |
| Weighted average shares, diluted (in shares) | 22,171,309 | 10,622,720 | 6,539,760 | 5,835,682 |
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC. (ADIL)